renaissance capital

The death knell for SPACs?

It was a tough day for special purpose acquisition companies, or SPACs, which had already fallen out of favor after roughly 18 months in the limelight. First, Senator Elizabeth Warren announced today

Why 2022 insurtech investment could surprise you

Insurtech startups that can retain a tech multiple have a shot at keeping their valuation intact; those that don’t may struggle.

The year of the disappearing lock-up

That startup founders are in the driver’s seat has been plain for a while now. Consider the extent to which funding has soared, with investors reportedly plugging a record $93 billion into early

Unicorns Braze and UserTesting begin public life in diverging ways

Braze priced above its IPO range, while UserTesting priced underneath its range. Why?

Backblaze’s IPO a test for smaller tech concerns

Backblaze's IPO is a harkening back to the time when it was somewhat difficult to convince private-market investors to value your company in the nine-figures, let alone 10.

Udemy targets valuation of $4B in major edtech IPO

Udemy's slowing revenue growth is not bullish for edtech valuations more broadly; the company's modest resulting revenue multiple is also somewhat beige.

It turns out fintech is worth as much as SaaS

The lesson appears to be that revenue growth matters more than near-term margins for fintech companies, allowing them to secure valuations that far surpass their final private marks.

Indications of a hot market abound as Freshworks, Toast price IPOs

Toast and Freshworks both raised their IPO ranges and priced above the raised interval. If you are looking for an indication that it's a good time to go public, this is it.

Freshworks’ valuation could crest $10B in upcoming IPO

Freshworks now expects to charge between $32 and $34 per share in its debut, up from the $28 to $32 per-share range that it initially disclosed.

What to make of Freshworks’ first IPO price range

It appears that Freshworks is pretty reasonably priced in its current range.

Is a direct listing the right choice for your company?

Before you decide what’s right for your company, here are a few things you need to know about direct listings.

While tech waffles on going public, biotech IPOs boom

With our fixation on all things tech, we’re missing out on the big picture -- there are actually more biotech and healthcare startup IPOs than tech offerings.

Experts think the IPO window could finally bust open in the second quarter

Renaissance Capital, the IPO research firm, has published a new report about the first quarter of this year, and, as you might expect, it doesn’t paint a pretty picture. For starters, it notes t

The IPO Boom Is Back: Pricings Hit A 12-Year High, With Tech Stocks Leading The Way

It's official: We're back in boom times from a tech IPO standpoint. 2012 is now on pace to be a record-breaking year for initial public offerings, and technology companies are leading the way. Fif